Table 1.
Dose response of HPI-4 and vismodegib on ASMCs in the collagen gel contraction assay
| Drug | Contraction at 24 h, % | Contraction at 40 h, % | Percent Contraction 0–24 h* | Percent Contraction 0–40 h* |
|---|---|---|---|---|
| HPI-4 | ||||
| DMSO control | 60.896 ± 2.322 | 65.595 ± 2.464 | ||
| HPI-4 (5 μM) | 58.033 ± 2.550 | 56.229 ± 2.971 | NS | P < 0.05 |
| HPI-4 (10 μM) | 56.501 ± 1.521 | 61.011 ± 1.825 | NS | NS |
| HPI-4 (15 μM) | 41.134 ± 3.115 | 48.655 ± 1.769 | P < 0.001 | P < 0.001 |
| Vismodegib | ||||
| DMSO control | 60.832 ± 1.525 | 73.952 ± 1.620 | ||
| Vismodegib (15 μM) | 55.219 ± 0.4298 | 66.982 ± 1.323 | P < 0.05 | P < 0.01 |
| Vismodegib (30 μM) | 49.281 ± 3.609 | 62.673 ± 4.078 | P < 0.05 | P < 0.05 |
| Vismodegib (45 μM) | 60.465 ± 2.295 | 68.383 ± 3.207 | NS | NS |
Values are means ± SE; n = 3 gels analyzed per group.
*
Statistical comparisons were made using one-way ANOVA, Holm-Sidak post hoc testing, using Prism GraphPad Prism software, version 7.0b. Comparisons were made between DMSO control and dose groups. NS, not significant.